Cardiovascular

FDA drops certain restrictive requirements for Nplate and Promacta

The U.S. Food and Drug Administration has announced changes to the Risk Evaluation and Mitigation Strategies for Nplate (romiplostim) and Promacta (eltrombopag). Among the changes: Healthcare professionals are no longer required to complete periodic safety forms for patients either drug. In addition, healthcare professionals, hospitals, specialty care facilities, and patients are no longer required to be enrolled in the Nplate NEXUS (Network of Experts Understanding and Supporting Nplate and Patients) Program or the Promacta CARES Program to prescribe, dispense or receive the drugs. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares